Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalti... Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates. Show more
Royalty Pharma inaugural Prize for Impact in Healthcare awarded to Michael Milken, the founder of the Milken Institute, Faster Cures & the Prostate Cancer FoundationThe Prize includes a...
RYTELO™ (imetelstat) is FDA approved for the treatment of low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemiaTransaction increases Royalty Pharma’s synthetic...
Portfolio Receipts growth of 15% to $735 million; Royalty Receipts growth of 15%Net cash provided by operating activities of $704 millionCapital Deployment of approximately $1.2 billion Raising...
Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800...
Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™ PR Newswire WALTHAM, Mass. and NEW YORK, Nov. 4, 2024 Proceeds expected to support the...
NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2024 financial results on Wednesday, November 6, 2024 before...
NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2024 of $0.21 per Class A...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.595 | 2.29818462727 | 25.89 | 26.665 | 25.1001 | 4144866 | 25.86402178 | CS |
| 4 | -0.755 | -2.77165932452 | 27.24 | 28.36 | 25.1001 | 2931349 | 26.38961386 | CS |
| 12 | -2.365 | -8.19757365685 | 28.85 | 29.37 | 25.1001 | 2311686 | 27.32544721 | CS |
| 26 | -0.845 | -3.09184046835 | 27.33 | 29.37 | 25.1001 | 2548366 | 27.22028043 | CS |
| 52 | -0.425 | -1.57933853586 | 26.91 | 31.655 | 25.1001 | 2622677 | 28.03845676 | CS |
| 156 | -15.755 | -37.2987689394 | 42.24 | 44.75 | 25.1001 | 2186043 | 33.33979066 | CS |
| 260 | 25.815 | 3852.98507463 | 0.67 | 57.5 | 0.67 | 2190928 | 36.61548909 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
